We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. NASHVILLE, Tenn. — Initiation of oral selexipag within ...

This approval allows the company to enter the market with a generic equivalent of Uptravi® for injection, which is originally produced by Actelion Pharmaceuticals US, Inc. Notably, the manufacturing ...

Patients with pulmonary arterial hypertension treated with a new oral, selective IP prostacyclin-receptor agonist had a lower risk for the primary composite endpoint of death or pulmonary arterial ...

A series of 5 cases highlights different opportunities to incorporate selexipag into the care of patients with pulmonary arterial hypertension, potentially eliminating risks associated with parenteral ...

"We had no preconceived idea if this drug would improve exercise capacity," said Luke Howard, MD, from Imperial College Healthcare NHS Trust in London. It was clear, however, that 6-minute walk tests ...

The US Food and Drug Administration (FDA) has approved the orphan drug selexipag (Uptravi, Actelion) for treatment of adults with pulmonary arterial hypertension (PAH), a chronic and progressive rare ...

The oral presentation, entitled `Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension: results of the GRIPHON study` will be given by Professor Vallerie McLaughlin of the ...

This study showed that treatment with selexipag (dosage increment from 200 mcg to 1600 mcg twice daily) reduced the risk of a morbidity/mortality event by 39% compared to placebo. The efficacy profile ...

Twice-daily selexipag was associated with improvements in 6-minute walk distance and potential maintenance or improvement in World Health Organization functional class in patients with pulmonary ...

Use of selexipag in patients with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) resulted in outcomes similar to those seen in patients with idiopathic PAH, despite the ...

New Delhi: Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) ...

Selexipag (trade name: Uptravi) is approved for long-term treatment of pulmonary arterial hypertension (PAH) in adults with moderate to severe symptoms. The drug can be used either as combination ...